Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA run

Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late-stage trial of its antiviral monoclonal antibody brelovitug.